J Am Pharm Assoc (2003)

• 

  Publication Venue For

  • Feasibility of a pharmacist-led symptom monitoring and management intervention to improve breast cancer endocrine therapy adherence..  62:1321-1328.e3. 2022
  • Impact of a clinical pharmacist on provider prescribing patterns in a primary care clinic..  62:209-213.e1. 2022
  • Impact of pharmacist outreach on glucagon prescribing..  62:1384-1388.e1. 2022
  • Reducing high-risk medication use through pharmacist-led interventions in an outpatient setting..  60:e86-e92. 2020
  • The possible harms of statins: What do product labels, patient package inserts, and pharmacy leaflets tell us?.  59:195-201. 2019
  • Pharmacists' experience with prescribing hormonal contraception in Oregon..  58:608-613. 2018
  • Pharmacist prescription of hormonal contraception in Oregon: Baseline knowledge and interest in provision..  56:521-526. 2016
  • Community pharmacists' experience with pharmacogenetic testing..  55:587-594. 2015
  • Health care providers' use of a drug information service for pregnancy-related inquiries..  54:502-509. 2014
  • Implementation of a pharmacogenomics service in a community pharmacy..  54:172-180. 2014
  • Factors affecting Medicare Part D beneficiaries' decision to receive comprehensive medication reviews..  53:482-487. 2013
  • Making pharmacogenetic testing a reality in a community pharmacy..  52:e259-e265. 2012
  • Safety-focused medication therapy management: a randomized controlled trial..  52:603-612. 2012